Affymetrix Inc (AFFX) 14.01 $AFFX
Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors
GlobeNewswire - 2 hrs 18 mins ago
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company's Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
SELB: 10.99 (+0.12), AFFX: 14.01 (+0.02)
Uptrend Call Working As Affymetrix Stock Rises 48.1% (AFFX)
Comtex SmarTrend(R) - Fri Jul 29, 12:39AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 9 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Shares of AFFX Up 48.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 06, 1:04PM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 8 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
48.1% Return Seen to Date on SmarTrend Affymetrix Call (AFFX)
Comtex SmarTrend(R) - Tue Jun 14, 12:35AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 8 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Global Biochip Industry
PR Newswire - Tue Jun 07, 5:40PM CDT
This report analyzes the worldwide markets for Biochips in US$ Million by the following Segments: DNA Biochips, Protein Biochips, Lab-on-a-Chip, and Others. The report further analyzes the market by the following Applications: Research, Diagnostics, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 79 companies including many key and niche players such as -
A: 48.11 (+0.60), AFFX: 14.01 (+0.02)
Affymetrix Has Returned 48.1% Since SmarTrend Recommendation (AFFX)
Comtex SmarTrend(R) - Fri May 27, 1:03PM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 7 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Affymetrix Shares Up 48.1% Since SmarTrend's Buy Recommendation (AFFX)
Comtex SmarTrend(R) - Fri May 20, 12:31AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 7 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Affymetrix Up 48.1% Since SmarTrend Uptrend Call (AFFX)
Comtex SmarTrend(R) - Thu May 05, 12:44AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 6 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by Affymetrix Stockholders
BusinessWire - Thu Mar 31, 12:30PM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Affymetrix, Inc. (NASDAQ: AFFX), a leading provider of cellular and genetic analysis products, today announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion. Completion of the transaction follows approval of the merger agreement by Affymetrix stockholders at the special meeting held today.
TMO: 158.84 (+0.02), AFFX: 14.01 (+0.02)
WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 61.01 (-0.08), TMO: 158.84 (+0.02), SUNE: 0.34 (unch), SCLN: 10.56 (+0.15), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Affymetrix, Inc.
PR Newswire - Wed Mar 30, 11:28AM CDT
Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, case no. 3:16-cv-00921, on behalf of shareholders of Affymetrix, Inc. ("Affymetrix" or the "Company"
(NasdaqGS:AFFX) who held Affymetrix securities on the record date, February 18, 2016, and have been harmed by Affymetrix's and its board of directors' (the "Board" alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act" in connection with the proposed sale of the Company to Thermo Fisher Scientific Inc. ("Thermo Fisher".
AFFX: 14.01 (+0.02)
Thermo Fisher to Acquire Affymetrix, Origin's Bid Falls Flat
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:40PM CDT
On completion, the Thermo Fisher(TMO)-Affymetrix (AFFX) deal is expected to generate attractive financial returns
TMO: 158.84 (+0.02), AFFX: 14.01 (+0.02), HRC: 53.43 (+0.84), OSUR: 6.82 (+0.23)
Selecta Biosciences Appoints Timothy C. Barabe to Board of Directors
GlobeNewswire - 2 hrs 18 mins ago
Selecta Biosciences, Inc. (NASDAQ:SELB), a clinical-stage biopharmaceutical company developing targeted antigen-specific immune therapies for rare and serious diseases, today announced the election of Timothy C. Barabe to the company's Board of Directors. Most recently serving as chief financial officer and executive vice president at Affymetrix Inc., Mr. Barabe has extensive experience in the life sciences industry, having held a broad range of financial and strategic roles.
SELB: 10.99 (+0.12), AFFX: 14.01 (+0.02)
Uptrend Call Working As Affymetrix Stock Rises 48.1% (AFFX)
Comtex SmarTrend(R) - Fri Jul 29, 12:39AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 9 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Shares of AFFX Up 48.1% Since Uptrend Call on Shares
Comtex SmarTrend(R) - Wed Jul 06, 1:04PM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 8 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
48.1% Return Seen to Date on SmarTrend Affymetrix Call (AFFX)
Comtex SmarTrend(R) - Tue Jun 14, 12:35AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 8 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Global Biochip Industry
PR Newswire - Tue Jun 07, 5:40PM CDT
This report analyzes the worldwide markets for Biochips in US$ Million by the following Segments: DNA Biochips, Protein Biochips, Lab-on-a-Chip, and Others. The report further analyzes the market by the following Applications: Research, Diagnostics, and Others. The report provides separate comprehensive analytics for the US, Canada, Japan, Europe, Asia-Pacific, Latin America, and Rest of World. Annual estimates and forecasts are provided for the period 2014 through 2020. Also, a seven-year historic analysis is provided for these markets. Market data and analytics are derived from primary and secondary research. Company profiles are primarily based on public domain information including company URLs. The report profiles 79 companies including many key and niche players such as -
A: 48.11 (+0.60), AFFX: 14.01 (+0.02)
Affymetrix Has Returned 48.1% Since SmarTrend Recommendation (AFFX)
Comtex SmarTrend(R) - Fri May 27, 1:03PM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 7 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Affymetrix Shares Up 48.1% Since SmarTrend's Buy Recommendation (AFFX)
Comtex SmarTrend(R) - Fri May 20, 12:31AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 7 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Affymetrix Up 48.1% Since SmarTrend Uptrend Call (AFFX)
Comtex SmarTrend(R) - Thu May 05, 12:44AM CDT
SmarTrend identified an Uptrend for Affymetrix (NASDAQ:AFFX) on October 28th, 2015 at $9.46. In approximately 6 months, Affymetrix has returned 48.10% as of today's recent price of $14.01.
AFFX: 14.01 (+0.02)
Thermo Fisher Scientific Completes Acquisition of Affymetrix Following Approval of Transaction by Affymetrix Stockholders
BusinessWire - Thu Mar 31, 12:30PM CDT
Thermo Fisher Scientific Inc. (NYSE: TMO), the world leader in serving science, and Affymetrix, Inc. (NASDAQ: AFFX), a leading provider of cellular and genetic analysis products, today announced that Thermo Fisher has completed its previously announced acquisition of Affymetrix for $14.00 per share in cash, for a total purchase price of approximately $1.3 billion. Completion of the transaction follows approval of the merger agreement by Affymetrix stockholders at the special meeting held today.
TMO: 158.84 (+0.02), AFFX: 14.01 (+0.02)
WebMD Health Set to Join the S&P MidCap 400; SciClone Pharmaceuticals to Join S&P SmallCap 600
PR Newswire - Wed Mar 30, 5:24PM CDT
S&P Dow Jones Indices will make the following changes to the S&P MidCap 400 and S&P SmallCap 600 indices after the close of trading on Friday, April 1:
WBMD: 61.01 (-0.08), TMO: 158.84 (+0.02), SUNE: 0.34 (unch), SCLN: 10.56 (+0.15), MHFI: 107.92 (+1.16), AFFX: 14.01 (+0.02)
Faruqi & Faruqi, LLP Announces Filing of a Class Action Lawsuit Against Affymetrix, Inc.
PR Newswire - Wed Mar 30, 11:28AM CDT
Notice is hereby given that Faruqi & Faruqi, LLP has filed a class action lawsuit in the United States District Court for the Northern District of California, case no. 3:16-cv-00921, on behalf of shareholders of Affymetrix, Inc. ("Affymetrix" or the "Company"
(NasdaqGS:AFFX) who held Affymetrix securities on the record date, February 18, 2016, and have been harmed by Affymetrix's and its board of directors' (the "Board" alleged violations of Sections 14(a) and 20(a) of the Securities Exchange Act of 1934 (the "Exchange Act" in connection with the proposed sale of the Company to Thermo Fisher Scientific Inc. ("Thermo Fisher". AFFX: 14.01 (+0.02)
Thermo Fisher to Acquire Affymetrix, Origin's Bid Falls Flat
Zacks Equity Research - Zacks Investment Research - Tue Mar 29, 1:40PM CDT
On completion, the Thermo Fisher(TMO)-Affymetrix (AFFX) deal is expected to generate attractive financial returns
TMO: 158.84 (+0.02), AFFX: 14.01 (+0.02), HRC: 53.43 (+0.84), OSUR: 6.82 (+0.23)
